Biomerica, Inc. Reports Earnings Results for the Second Quarter Ended November 30, 2019
January 14, 2020 at 04:18 pm EST
Share
Biomerica, Inc. announced earnings results for the second quarter ended November 30, 2019. For the second quarter, the company announced sales was USD 1.596 million compared to USD 1.500 million a year ago. Operating loss was USD 489,743 compared to USD 485,937 a year ago. Net loss was USD 485,260 compared to USD 477,244 a year ago. Basic loss per share from continuing operations was USD 0.05 compared to USD 0.05 a year ago. For the half year, sales was USD 2.790 million compared to USD 2.773 million a year ago. Operating loss was USD 1.000 million compared to USD 940,723 a year ago. Net loss was USD 991,556 compared to USD 928,984 a year ago. Basic loss per share from continuing operations was USD 0.1 compared to USD 0.1 a year ago.
Biomerica, Inc. is a biomedical technology company. The Company develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (in home and in physiciansâ offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. It is also engaged in the research, development, commercialization and in certain cases regulatory approval, of patented, diagnostic-guided therapy (DGT) products to treat gastrointestinal diseases, such as irritable bowel syndrome (IBS), and other inflammatory diseases. The Company's InFoods IBS product uses a simple blood sample and is designed to identify patient-specific foods that, when removed from the diet, may alleviate IBS symptoms such as pain, bloating, diarrhea and constipation. The Companyâs two subsidiaries, Biomerica de Mexico, which is used for assembly/manufacturing and BioEurope GmbH, which acts as a distributor of Biomerica products in certain markets.
BIOMERICA, INC. 
